Navigation Links
Vasogen Announces 2007 Year-End Results
Date:1/16/2008

journal. As

previously reported by Vasogen, while the trial did not meet its

primary endpoint, a key finding from the ACCLAIM trial was a

39% reduction in the risk of death or cardiovascular hospitalizations

for a large pre-specified subgroup of patients with NYHA Class II

heart failure who received Celacade therapy, compared to patients

receiving placebo.

- We entered into a collaboration with Grupo Ferrer Internacional,

S.A., a leading European pharmaceutical and medical devices company,

to commercialize Celacade for the treatment of chronic heart failure

in specified countries of the European Union and in certain Latin

American countries. In December 2007, Ferrer received initial orders

for Celacade in Germany.

- The Food and Drug Administration strongly recommended that we conduct

a confirmatory study (ACCLAIM-II) in NYHA Class II heart failure

patients to support a Pre-market Approval filing for Celacade in the

United States. The FDA also recommended that we utilize a Bayesian

statistical approach for designing the confirmatory trial as it would

allow for the borrowing of statistical power from the ACCLAIM study.

This approach has the potential to substantially reduce the number of

patients required for a confirmatory study, as well as the cost and

duration.

- James B. Young, MD, Chairman, Division of Medicine at the Cleveland

Clinic Foundation and Medical Director, Kaufman Center for Heart

Failure, was appointed the Global Principal Investigator and Chairman

of the Steering Committee for ACCLAIM-II.

- Chris Waddick, MBA, CMA, was appointed President, CEO, and a Member

of the Board of Directors of our Company. Mr. Waddick has held a

series of progressive senior management positions at Vasog
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
9. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
10. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
11. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Jose, California (PRWEB) March 04, 2015 ... Reaction (PCR) represents one of the fastest growing technologies ... cell biologists in subcellular visualization is driving growth in ... need for deeper understanding of gene expressions will continue ... market. Expanding applications in fields ranging from pharma, biotech, ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
(Date:3/3/2015)... GUELPH, ON , March 3, 2015 /PRNewswire/ - BIOREM Inc. ... totalling $3.7 million.  The orders are for odour control projects in ... and Asia . "Bidding ... Webb , President and CEO. "After a high volume year for ... continue into the New Year.  The recent orders reflect the organization,s ...
(Date:3/3/2015)... , March 3, 2015 Adaptive Biotechnologies announced ... is joining its Board of Director as Chair of ... at Zillow Group, Chad oversees all finance, treasury and ... the company,s core finance, treasury and accounting functions, and ... nine acquisitions. In 2013, he was named Puget Sound ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2
... 2011 Clinical Research Management, (ClinicalRM) a full-service ... applied research, clinical trials, and regulatory support, announced ... Navy Medical Research Center (NMRC) under its Omnibus ... resources in support of NMRC, including: providing an ...
... Davis School of Medicine have outlined several approaches to ... under scrutiny by the U.S. National Institutes of Health. ... Medicine in a focus article titled, "Creating the ... www.ScienceTranslationalMedicine.org . "In this era of ...
... be best known as a symbol of long-lasting love. ... as key components of long-lasting micromachines if a new ... Technology (NIST) for carving these tough, capable crystals proves ... engineer microscopic cuts in a diamond surface, yielding potential ...
Cached Biology Technology:ClinicalRM Awarded Omnibus III Contracts to Support the Navy Medical Research Center (NMRC) 2ClinicalRM Awarded Omnibus III Contracts to Support the Navy Medical Research Center (NMRC) 3UC Davis advocates for new approaches to biomedical research 2UC Davis advocates for new approaches to biomedical research 3NIST polishes method for creating tiny diamond machines 2
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has ... Market Overview" report to their offering. , ... that an individual is who she/he is claiming to be, ... a person,s unique physical characteristics, such as fingerprint, hand or ...
(Date:1/22/2015)... , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the leading source ... launch of its new website design. "When we ... infancy", says Peter O,Neill , founder and CEO of ... industry needs involvement from the key players on a very ...
(Date:1/22/2015)... Technology Showcase, Hall E -   EyeLock Inc. , a ... will showcase its EyeLock ID technology integrated in a 3D ... Oak Ridge National Laboratory (ORNL) at the 2015 ... authentication technology is being used to validate the driver and ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... Va.Catheter Lysis of Thromboembolic Stroke (CLOTS)an intensive five-day ... Oct. 24-28 in Dallas, Texasprovides interventional radiologists, neurointerventionalists, ... opportunity to review, observe and discuss all aspects ... the third-leading cause of death in the United ...
... 2010 A yearlong beach study led by a ... at sub-tropical beaches face an increased risk of illness. ... beachgoers face when exposed to recreational marine water at ... contamination. B.E.A.C.H.E.S. (Beach Environmental Assessment and ...
... Calif. , July 28 DigitalPersona, ... protection solutions, today announced DigitalPersona® Pro Enterprise, a ... protection and communication security.  DigitalPersona Pro Enterprise helps ... mobile workforces -- full disk encryption (FDE), two-factor ...
Cached Biology News:Explore stroke care with Society of Interventional Radiology's CLOTS 2Study suggests swimmers at sub-tropical beaches show increased risk of illness 2DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 2DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 3DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security 4
... Recombinant Enterokinase (rEK) is a highly purified ... enterokinase, a serine protease which recognizes the ... (AspAspAspAspLys?) and has similar enzymatic activity (1). ... and purified to yield the highest activity ...
... of a Hybridizer and UV Crosslinker (254nm UV) ... , This unique, new design for the ... one location , Hybridizer and Crosslinker portions ... , The Crosslinker is also available as ...
Preparation Note: Prepared essentially by method of Singer, T.P., J. Biol. Chem., 174, 11 (1948). Quality Clarifier: Contains lipase Unit Definition: One unit will hydrolyze 1.0 μmole of p-ni...
... is a high performance spectral scanning ... incubator. With the advanced SkanIt Software ... for drug discovery assay development. Varioskan ... intensity, time-resolved fluorescence and photometric assays ...
Biology Products: